依达拉奉右莰醇联合丹红治疗急性脑梗死患者效果及对血液流变学与miR-34c的影响

Effect of Edaravone Dexborneol Combined with Danhong in the Treatment of Acute Cerebral Infarction Patients and Its Influence on Hemorheology and miR-34c

目的:研究依达拉奉右莰醇联合丹红注射液治疗急性脑梗死(ACI)患者的临床效果及对患者血液流变学与血清miR-34c水平的影响。方法:选取2021年8月—2023年2月104例入住在赣南医科大学第三附属医院的ACI患者作为研究对象,随机分为单一组和联合组。两组均进行常规治疗,在此基础上,单一组给予丹红注射液治疗,联合组给予依达拉奉右莰醇联合丹红注射液治疗,两组均治疗2周。观察患者治疗后临床疗效、治疗前后的神经功能、日常生活能力、血液流变学各指标和不良反应,抽取血样检测血清超氧化物歧化酶(SOD)、超敏C反应蛋白(hs-CRP)和miR-34c水平的变化。结果:治疗后联合组总有效率为90.38%,明显高于单一组的75.00%,两组差异有统计学意义(P<0.05)。治疗1、2周后,两组NIHSS评分、血液流变学各指标和hs-CRP水平均明显降低,且联合组均显著低于单一组(P<0.05);而Barthel指数评分、血清SOD和miR-34c水平均明显升高,且联合组均显著高于单一组(P<0.05)。两组的不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:使用达拉奉右莰醇联合丹红注射液治疗ACI患者可以增强治疗效果和日常生活能力,改善患者的神经功能和血液流变学参数,并且能够提高血清miR-34c水平以抑制炎症反应。

Objective:To investigate the clinical efficacy of Edaravone Dexborneol and Danhong Injection in the treatment of patients with acute cerebral infarction(ACI)and their effects on hemorheology and serum miR-34c levels.Method:Between August 2021 and February 2023,104 ACI patients admitted to the Third Affiliated Hospital of Gannan Medical University were selected as the study subjects and randomly divided into the single group and the combination group.Both groups received routine treatment,and on the basis of routine treatment,the single group received Danhong Injection treatment while the combination group received Edaravone Dexborneol and Danhong Injection treatment.Both groups were treated for 2 weeks.The clinical efficacy,neurologic function,activities of daily living,hemorheology indexes before and after treatment,and adverse reactions were observed in the patients.Blood samples were collected to detect the changes in serum superoxide dismutase(SOD),high-sensitivity C reactive protein(hs-CRP)and miR-34c levels.Result:The total effective rate of the combination group after treatment was 90.38%,significantly higher than 75.00%of the single group,the difference between two groups was statistically significant(P<0.05).After 1 week and 2 weeks of treatment,the NIHSS scores,various indicators of hemorheology and hs-CRP levels in both groups were significantly reduced,and those of the combination group were significantly lower than those of the single group(P<0.05);the Barthel index score,serum SOD and miR-34c levels were significantly increased,and those of the combination were significantly higher than those of the single group(P<0.05).There were no statistically significant differences in the incidences of adverse reactions between two groups(P>0.05).Conclusion:The combination of Edaravone Dexborneol and Danhong Injection in the treatment of patients with ACI can improve the clinical efficacy and activities of daily living,improve neurologic function and hemorheology,and upregulate serum miR-34c levels to inhibit inflammatory responses.